Accelerating Research for Early Development of Innovative Antibodies


Bernard MAILLÈRE – UMR 0496
CEA – INRAE – Paris Saclay University
Medecine and Healthcare Technologies Department

Key words

Antibody drug-conjugate (ADC)
Inhaled antibody

Key figures
  • Budget : 5,2 M€
  • Durée : 4 years (2023 – 2027)

In the last two decades, antibodies have definitively demonstrated their clinical benefits and occupy now a large part of the drug market. Unfortunately, few antibodies have been developed in France and only four are produced in France from approximately one hundred approved antibodies.

The costs of antibodies remain high due to development and production costs, although large progresses have been made in their bioproduction but also due to the attrition rate between the different development phases. Many antibodies resulting from activity screenings cannot become drugs, owing to their low production capacity, low stability, high immunogenicity or propensity to aggregate.

New antibody formats and scaffolds have emerged in the recent years and appear to be very promising therapeutic molecules. Further, delivery of antibodies by the airways have been poorly investigated, although it could be an effective way for the treatment of respiratory diseases but not only.

The ACCREDIA consortium has the ambition

  • to improve the selection of innovative antibodies by mastering their developability from the early phases of development, developability being the set of properties that make an innovative antibody can become a drug ;
  • to optimize the bioproduction of antibody formats (sequences, formats, isotypes, ADCs, multi-specifics) and scaffolds (VHH, affitin) by comparing the possible choices for their in vitro and in vivo activity and their ease of production (expression, purification, storage) ;
  • to propose industrializable solutions for innovative antibody formats that are adapted to inhalation.

The strategy is mainly based on the use of high throughput approaches of antibody engineering, bioinformatics, chemical engineering, radiolabeling and biodistribution investigations to reveal general parameters in the sequence contributing to their developability, to improve the choice of formats for antibodies, ADC and multi-specifics and to optimize the formats and modalities of antibody administration by inhalation.

Beyond the development of innovative methodologies and new antibodies, ACCREDIA structures a network of academic laboratories in the field of antibody design and bioproduction that should strengthen partnerships with industry and start-ups in the near future.

Coordinating partner : Bernard MAILLÈRE – UMR 0496
CEA – INRAE – Paris Saclay University
Medecine and Healthcare Technologies Department
Pierre MARTINEAU – UMR 1194
Inserm – Montpellier Univsersity
Montpellier Cancer Research Institute
Nathalie HEUZE-VOURC‘H – UMR 1100
Inserm – Tours University
Center for the Study of Respiratory Pathologies (CEPR)
Inserm – Paris Saclay University
Inflammation, Microbiome and Immunosurveillance
Myriam TAVERNA – UMR 8612
CNRS – Paris Saclay University
Institut Galien Paris-Saclay (IGPS)
Frédéric PECORARI – UMR 1302 / ERL 6001
CNRS – Inserm – Nantes University
Immunology and new concepts in immunotherapy (INCIT)
Pierre BRUHNS – UMR 1222
Inserm – Institut Pasteur
Antibodies in Therapy and Pathology